NCT04119115|Terminated
Study Stopped
Lack of resources and funding
Integrated Radiographic and Metabolomics Risk Assessment in Patients With Interstitial Lung Diseases
IRM-ILD
Loading search results
Sponsor study identifier
observational
28
1 country
1
Study Start
September 30, 2021
Actual (reported)Primary Completion
October 20, 2022
Actual (reported)Study Completion
October 20, 2022
Actual (reported)The purpose of this study is to find out if combining a state-of-the-art form imaging modality with metabolomics in different types of Interstitial Lung Diseases (ILD) patients compared to controls with chronic obstructive pulmonary disorder (COPD)/emphysema and healthy controls will be a better predictor of disease progression. ILD's are a group of chronic, progressive lung diseases. The most common ILD is idiopathic pulmonary fibrosis (IPF). Metabolomics provides a "snapshot" in time of all metabolites present in a biological sample. The imaging procedure should take approximately 20 minutes. All study related collections of samples will be done in a single visit if possible. There are no direct benefits to participants. This is not a treatment study.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 20, 2022
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 3, 2019
Actual (reported)October 8, 2019
Actual (reported)September 30, 2021
Actual (reported)October 20, 2022
Actual (reported)October 20, 2022
Actual (reported)Quantitative image lung function
CT-V scores between inhalation and exhalation will be calculated at a voxel level on each lung using the "Integrated Jacobian Formulation" (IJV) CT-V method in patients with IPF, non-IPF ILD and COPD/emphysema patients. Several factors, including the volume of identified "cold spots" (areas with decreased ventilation), total ventilation (the integral of CT-V image over the whole lung), and texture analytics (local means, variances, etc.) will be used to define a CT-V pulmonary function metric. This measure is reported in liters with lower numbers indicating reduced lung function.
baseline
Forced Vital Capacity baseline
Maximum volume exhaled in liters measured on a spirometer at baseline
baseline
Untargeted Metabolic profile of breath
baseline
Untargeted Metabolic profile of Serum
baseline
CT-V and metabolite analysis of breath and serum at baseline
CT-V and metabolite analysis of breath and serum at baseline
Metabolite analysis of breath and serum at baseline
CT-V is a newer computed tomography scan which is more comprehensive and tracks movement of the lungs.
Pulmonary outpatient clinic and interstitial lung disease clinic at Beaumont Hospital, Royal Oak
Beaumont Health
Royal Oak, Michigan, 48073, United States
Girish B Nair, MD
Corewell Health East
28 participants (actual enrollment reported by the registry).
First Submitted
October 3, 2019
First Posted
October 8, 2019
Study Start
September 30, 2021
Actual (reported)Retrospective Validation of AccuPulmo CT Portal for Detecting Pulmonary Fibrosis on Chest CT
Metabolites are compounds which can be measured in biospecimens and may indicate a disease or biological process.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
October 20, 2022
Actual (reported)Study Completion
October 20, 2022
Actual (reported)Last Updated
May 3, 2023
Record last verified: 2023-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: